Ovarian cancer breakthrough? tumor slices could reveal best drug for each patient

NCT ID NCT06065358

Ongoing Knowledge-focused Sponsor: Fondazione Policlinico Universitario Agostino Gemelli IRCCS Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether thin slices of ovarian tumors, kept alive in the lab, can predict how a patient will respond to chemotherapy. Researchers will take tumor samples from 48 women with advanced ovarian cancer during surgery. They will then expose the slices to different drugs and compare the lab results to how the patients actually respond to treatment. If the method works, it could lead to personalized drug testing for ovarian cancer.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

What this could lead to: If successful, this method could help doctors quickly choose the most effective chemotherapy for each ovarian cancer patient, improving treatment outcomes.
What could go wrong: This is a small, early feasibility study with only 48 participants. The lab test may not accurately predict real patient responses, and results may not apply to all ovarian cancer types.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPITHELIAL OVARIAN CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

fallopian tube cancer ovarian cancer ovarian carcinoma primary peritoneal carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

OVARIAN CANCER

Contacts and locations

Locations

Fondazione Policlinico Universitario Agostino Gemelli IRCCS

Rome, Italy

More trials for these conditions

Other studies related to the condition(s) this trial covers.